This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PAHC vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. ABT: Which Stock Is the Better Value Option?
Why Is Boston Scientific (BSX) Up 7.5% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
by Zacks Equity Research
Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Hims & Hers Stock Gains 31.1% Since Q3 Earnings: What's Next?
by Debanjana Dey
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
The Zacks Analyst Blog Highlights like Amazon.com, Procter & Gamble, Abbott and NVE
by Zacks Equity Research
Amazon.com, Procter & Gamble, Abbott and NVE are part of the Zacks top Analyst Blog.
Top Stock Reports for Amazon.com, Procter & Gamble & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Procter & Gamble Co. (PG) and Abbott Laboratories (ABT), as well as a micro-cap stock NVE Corp. (NVEC).
PAHC or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. ABT: Which Stock Is the Better Value Option?
Medtronic Stock Trading at a Discount Before Q2 Earnings: Time to Buy?
by Urmimala Biswas
Like its peers, the impact of the present geopolitical situation may have curbed fiscal second-quarter profits for Medtronic.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
AngioDynamics Stock Plunges 13.8% in Three Months: What's Next?
by Debanjana Dey
ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance.
Here's Why You Should Retain ABT Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about Abbott's robust strength in the Diagnostics and Nutrition business. Yet, unfavorable forex impacts are concerning.
ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock
by Zacks Equity Research
Abbott initiates the TEAM-HF trial to improve outcomes for advanced heart failure.
HCA Healthcare Beats on Q3 Earnings, Reaffirms 2024 EPS View
by Zacks Equity Research
HCA's quarterly results benefit from improved admissions and inpatient surgeries, partially offset by the impact of hurricanes and rising salaries and benefits expenses.
Molina Healthcare Q3 Earnings Beat Estimates on Growing Premiums
by Zacks Equity Research
MOH's third-quarter results benefit from growing membership and rising premiums, partially offset by rising expenses.
Community Health Q3 Earnings Miss on Lower Adjusted Admissions
by Zacks Equity Research
CYH's third-quarter earnings suffer a setback due to lower admissions and patient days. Improved occupancy levels and reimbursement rates partially offset the negatives.
Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Top Research Reports for Visa, Netflix & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Netflix, Inc. (NFLX) and Merck & Co., Inc. (MRK), as well as a micro-cap stock Hovnanian Enterprises, Inc. (HOV).
MDT vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
MDT vs. ABT: Which Stock Is the Better Value Option?
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Company News for Oct 17, 2024
by Zacks Equity Research
Companies In The News Are: ABT, CFG, FHN, IBKR.
Abbott Stock Gains on Q3 Earnings Beat, Margins Expand
by Zacks Equity Research
ABT delivers a strong underlying base business performance in the third quarter of 2024.